Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, discusses the data from the Phase III IMvigor130 trial (NCT02807636) being presented at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. This study evaluated atezolizumab monotherapy and atezolizumab with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma.